BioHarvest Sciences Inc. files Form 6-K current reports as a foreign issuer, with exhibits that document company announcements and material changes. These filings cover the company's Botanical Synthesis platform, its VINIA-branded nutraceutical products, CDMO activities for plant-based compounds, earnings-call announcements, and business updates.
The filing record also includes governance and capital-structure subjects such as board composition changes, executive leadership transitions, long-term incentive awards, stock options, restricted share units, and equity incentive plan activity. Together, the disclosures provide formal records of BioHarvest's operating focus, public-company governance, compensation structure, and recurring communications to the market.
BioHarvest Sciences shares a year-end update highlighting its first full year as a Nasdaq-listed company, with an annualized revenue run rate above US$36 million and gross margins over 60%. Management describes 2025 as a year of execution and balance sheet strengthening, including raising about $30.8 million through warrant exercises, debt conversions, and an oversubscribed institutional equity financing.
The VINIA-branded direct-to-consumer line now has more than 85,000 active users, over 90% of Vinia.com sales via subscriptions, and a 4.7/5 rating from more than 10,000 reviews. The CDMO Services division signed anchor contracts across several industries, began work on two major plant-based compounds, and expects its revenues to eventually surpass the products division. The company plans to invest in a 100-ton manufacturing footprint and targets adjusted EBITDA breakeven while pursuing growth from both its D2C and CDMO businesses.
BioHarvest Sciences Inc. (BHST) launched a primary offering of 2,485,000 common shares. The shares are priced at $7.00 each, for gross proceeds of $17,395,000, less underwriting discounts of $1,192,688, with estimated net proceeds of approximately $15,802,200. The company granted a 30‑day option to the underwriter to purchase up to 372,750 additional shares.
Shares outstanding are expected to be 19,818,430 after the offering (or 20,191,180 if the option is fully exercised). Craig‑Hallum is the sole managing underwriter, with delivery expected on or about November 10, 2025. The company plans to use the proceeds for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes.
BioHarvest also provided preliminary results: Q3 2025 revenue is expected to be approximately $9.1M with adjusted EBITDA between negative $0.7M and negative $0.4M. Q4 2025 guidance calls for revenue of $9.0M to $9.5M and adjusted EBITDA between negative $0.6M and $0.0M.
BioHarvest Sciences Inc. launched a preliminary prospectus supplement for a primary underwritten offering of common shares on Nasdaq under “BHST,” with Craig‑Hallum as sole managing underwriter and a 30‑day option for the underwriter to buy additional shares after effectiveness. The company, a foreign private issuer and emerging growth company, plans to use proceeds for research and development, manufacturing, marketing, advancing its CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes.
Management also shared preliminary Q3 2025 results and Q4 guidance. Q3 revenue is expected at approximately $9.1M, with adjusted EBITDA in a range of ($0.7M) to ($0.4M). For Q4 2025, revenue guidance is $9.0M to $9.5M, with adjusted EBITDA between ($0.6M) and $0.0M. Recently, the company signed a CDMO agreement with Saffron Tech to develop saffron‑derived compounds; Saffron Tech will own 75% of developed compositions and related IP, while BioHarvest will hold 25% and intends to manufacture and market resulting products.